Skip to main content

Advertisement

SpringerLink
Log in

Oncology stewardship in acute myeloid leukemia

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

In recent years, an explosion of novel agents has shifted the treatment paradigm for patients with acute myeloid leukemia. The optimal place in therapy for many of these novel agents remains unknown due to limited guidance from national guidelines and the way these agents were studied prior to entering the market. A critical evaluation of the literature and incorporation of oncology stewardship principles can be helpful in determining an optimal place for these agents while being mindful of the overall cost that is associated with therapies. The purpose of this review is to critically evaluate the efficacy and safety data for five controversial agents and provide examples of the use of stewardship practices in determining their place in the treatment of acute myeloid leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yates JW, Wallace HJ, Ellison RR, Holland JF (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57(4):485–488

    CAS  PubMed  Google Scholar 

  2. National Cancer Institute Surveillance, Epidemiology, and End Results SEER) Program. Acute Myeloid Leukemia.: https://seer.cancer.gov/statfacts/html/amyl.html Accessed.

  3. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–59. https://doi.org/10.1056/NEJMoa061094

    Article  CAS  PubMed  Google Scholar 

  4. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249–1259. https://doi.org/10.1056/NEJMoa0904544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia Cancer and Leukemia Group B. N Engl J Med. 331(14):896–903. https://doi.org/10.1056/NEJM199410063311402

    Article  CAS  PubMed  Google Scholar 

  6. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P et al (1988) Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6(4):583–587. https://doi.org/10.1200/JCO.1988.6.4.583

    Article  CAS  PubMed  Google Scholar 

  7. Vaughan WP, Karp JE, Burke PJ (1980) Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 45(5):859–865. https://doi.org/10.1002/1097-0142(19800301)45:5%3c859::aid-cncr2820450506%3e3.0.co;2-z

    Article  CAS  PubMed  Google Scholar 

  8. Burke PJ, Karp JE, Braine HG, Vaughan WP (1977) Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 37(7 Pt 1):2138–2146

    CAS  PubMed  Google Scholar 

  9. National Comprehensive Cancer Network. Acute Myeloid Leukemia (Version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf Accessed.

  10. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J et al (2020) Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(6):697–712. https://doi.org/10.1016/j.annonc.2020.02.018

    Article  CAS  PubMed  Google Scholar 

  11. Howard DH, Bach PB, Berndt ER, Conti RM (2015) Pricing in the Market for Anticancer Drugs. J Econ Perspect 29(1):139–162. https://doi.org/10.1257/jep.29.1.139

    Article  PubMed  Google Scholar 

  12. Bach PB, Saltz LB, Wittes RE (2012) In cancer care, cost matters. New York Times. https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html

  13. Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T et al (2020) Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 21(5):664–670. https://doi.org/10.1016/S1470-2045(20)30139-X

    Article  CAS  PubMed  Google Scholar 

  14. National Comprehensive Cancer Network. Acute Myeloid Leukemia (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf Accessed.

  15. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P et al (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121(12):2213–2223. https://doi.org/10.1182/blood-2012-10-462879

    Article  CAS  PubMed  Google Scholar 

  16. Sawler D, Sanford D, Brandwein JM, Sandhu I, Hogge D, Saini L (2017) Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics. Blood 130:464

    Google Scholar 

  17. Mylotarg [Package insert]. Philadelphia, PA: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf

  18. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67(4):1048–1053

    Article  CAS  Google Scholar 

  19. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8(4):521–534. https://doi.org/10.1016/0145-2126(84)90001-8

    Article  CAS  PubMed  Google Scholar 

  20. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17(20):6417–6427. https://doi.org/10.1158/1078-0432.CCR-11-0486

    Article  CAS  PubMed  Google Scholar 

  21. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496

    CAS  PubMed  Google Scholar 

  22. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19(13):3244–3254. https://doi.org/10.1200/JCO.2001.19.13.3244

    Article  CAS  PubMed  Google Scholar 

  23. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854–4860. https://doi.org/10.1182/blood-2013-01-466706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361(13):1235–1248. https://doi.org/10.1056/NEJMoa0901409

    Article  PubMed  Google Scholar 

  25. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986–996. https://doi.org/10.1016/S1470-2045(14)70281-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30(32):3924–3931. https://doi.org/10.1200/JCO.2012.42.2964

    Article  CAS  PubMed  Google Scholar 

  27. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29(4):369–377. https://doi.org/10.1200/JCO.2010.31.4310

    Article  CAS  PubMed  Google Scholar 

  28. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508–1516. https://doi.org/10.1016/S0140-6736(12)60485-1

    Article  CAS  PubMed  Google Scholar 

  29. Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O et al (2011) Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediatecytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IRstudy. Blood 118(21):37–38

    Article  Google Scholar 

  30. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Anderson JE, Kopecky KJ, Willman CL, Head D, O’Donnell MR, Luthardt FW et al (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100(12):3869–3876. https://doi.org/10.1182/blood-2001-12-0354

    Article  CAS  PubMed  Google Scholar 

  32. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 31(27):3360–3368. https://doi.org/10.1200/JCO.2012.47.4874

    Article  CAS  PubMed  Google Scholar 

  33. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58(18):4173–4179

    CAS  PubMed  Google Scholar 

  34. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17(12):3767–3775. https://doi.org/10.1200/JCO.1999.17.12.3767

    Article  CAS  PubMed  Google Scholar 

  35. Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC et al (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22(6):1087–1094. https://doi.org/10.1200/JCO.2004.07.012

    Article  CAS  PubMed  Google Scholar 

  36. Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S, Huntly B et al (2021) Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. J Clin Oncol 39(8):890–901. https://doi.org/10.1200/JCO.20.01170

    Article  CAS  PubMed  Google Scholar 

  37. Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D et al (2019) Gemtuzumab ozogamicin for. Haematologica 104(1):113–119. https://doi.org/10.3324/haematol.2018.188888

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Godwin CD, McDonald GB, Walter RB (2017) Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129(16):2330–2332. https://doi.org/10.1182/blood-2017-01-762419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A et al (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol 61(6):1027–1035. https://doi.org/10.1007/s00280-007-0560-2

    Article  CAS  PubMed  Google Scholar 

  40. Löwenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121(1):26–28. https://doi.org/10.1182/blood-2012-07-444851

    Article  PubMed  Google Scholar 

  41. Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B et al (2011) Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29(19):2696–2702. https://doi.org/10.1200/JCO.2010.33.7303

    Article  CAS  PubMed  Google Scholar 

  42. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117(8):2366–2372. https://doi.org/10.1182/blood-2010-07-295279

    Article  CAS  PubMed  Google Scholar 

  43. Ochs MA, Perissinotti AJ, Marini BL, Burke PW, Bixby DL, Pettit KM et al (2021) Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. Leuk Res 102:106517. https://doi.org/10.1016/j.leukres.2021.106517

    Article  CAS  PubMed  Google Scholar 

  44. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374(23):2209–2221. https://doi.org/10.1056/NEJMoa1516192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Vidaza [Package insert]. Summit, NJ: Celgene Corporation; 2022. https://packageinserts.bms.com/pi/pi_vidaza.pdf

  46. Dacogen [Package insert]. Rockville, MD: Otsuka America Pharmaceutical Inc.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf

  47. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS et al (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375(21):2023–2036. https://doi.org/10.1056/NEJMoa1605949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31(3):705–711. https://doi.org/10.1038/leu.2016.263

    Article  CAS  PubMed  Google Scholar 

  49. Montero J, Letai A (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25(1):56–64. https://doi.org/10.1038/cdd.2017.183

    Article  CAS  PubMed  Google Scholar 

  50. Anderson MA, Huang D, Roberts A (2014) Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 51(3):219–227. https://doi.org/10.1053/j.seminhematol.2014.05.008

    Article  CAS  PubMed  Google Scholar 

  51. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G et al (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4(3):362–375. https://doi.org/10.1158/2159-8290.CD-13-0609

    Article  CAS  PubMed  Google Scholar 

  52. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971

    Article  CAS  PubMed  Google Scholar 

  53. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG et al (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724–e736. https://doi.org/10.1016/S2352-3026(20)30210-6

    Article  PubMed  PubMed Central  Google Scholar 

  54. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR et al (2021) Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. https://doi.org/10.1002/cncr.33689

    Article  PubMed  PubMed Central  Google Scholar 

  55. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791–803. https://doi.org/10.1182/blood.2019003988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R et al (2020) Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681–5689. https://doi.org/10.1182/bloodadvances.2020003120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, et al (2021) Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States [abstract]. Blood;Abstract 277.

  58. Chen S, Xie J, Yang X, Shen H, Cen J, Yao L, et al (20210 Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial [abstract]. Blood. Abstract 35.

  59. Garcia JS, Wolach O, Vachhani P, Zeidner JF, Talati C, Pollyea DA, et al (2021) Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative [abstract]. Blood. Abstract 2328.

  60. Sahasrabudhe KD, Rebechi MT, Huang Y, Behbehani GK, Bhatnagar B, Blachly JS, et al (2021) Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60–75 [abstract]. Blood. Abstract 4125.

  61. Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R et al (2022) Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant 57(2):160–166. https://doi.org/10.1038/s41409-021-01476-7

    Article  CAS  PubMed  Google Scholar 

  62. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K et al (2016) TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122(22):3484–3491. https://doi.org/10.1002/cncr.30203

    Article  CAS  PubMed  Google Scholar 

  63. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ et al (2021) Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282–291. https://doi.org/10.1002/ajh.26061

    Article  CAS  PubMed  Google Scholar 

  64. Gaidzik VI, Mayr-Benedikter V, Weber D, et al (2020) Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30–18 Trial. Presented at: 2020 ASH Annual Meeting; December 5–8, Virtual. Abstract 1043.

  65. Przespolewski AC, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, et al. (2019) Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis. J Clin Oncol. 37 : 15_suppl , e18530-e18530.

  66. Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M et al (2016) Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 34(9):972–979. https://doi.org/10.1200/JCO.2015.64.0060

    Article  CAS  PubMed  Google Scholar 

  67. Daurismo [Package insert]. New York, NY: Pfizer Inc; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf

  68. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T et al (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33(2):379–389. https://doi.org/10.1038/s41375-018-0312-9

    Article  CAS  PubMed  Google Scholar 

  69. Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B et al (2021) Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol 100(5):1181–1194. https://doi.org/10.1007/s00277-021-04465-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Arber DA, Orazi A, Hasserjian R, et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20):2391–2405. Blood. 2016;128(3):462–3. https://doi.org/10.1182/blood-2016-06-721662.

  71. Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G et al (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7):2137–2145. https://doi.org/10.1182/blood-2010-08-301713

    Article  CAS  PubMed  Google Scholar 

  72. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O’Brien S et al (2009) Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217–3221. https://doi.org/10.1002/cncr.24367

    Article  PubMed  Google Scholar 

  73. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE et al (2020) Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612–622. https://doi.org/10.1002/ajh.25769

    Article  CAS  PubMed  Google Scholar 

  74. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N et al (2009) In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33(1):129–139. https://doi.org/10.1016/j.leukres.2008.06.028

    Article  CAS  PubMed  Google Scholar 

  75. Sonneveld P, List AF (2001) Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 14(1):211–233. https://doi.org/10.1053/beha.2000.0124

    Article  CAS  PubMed  Google Scholar 

  76. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncol Group Stud Blood 89(9):3323–3329

    CAS  Google Scholar 

  77. da SilveiraJúnior LS, Soares VL, Jardim da Silva AS, Gil EA, Pereira de Araújo MDG, MercesGonçalves CA et al (2020) P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications. Int J Lab Hematol. 42(5):594–603. https://doi.org/10.1111/ijlh.13241

    Article  Google Scholar 

  78. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D (1990) Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 45(2):263–268. https://doi.org/10.1002/ijc.2910450210

    Article  CAS  PubMed  Google Scholar 

  79. Brunetti C, Anelli L, Zagaria A, Specchia G, Albano F (2017) CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds? Expert Rev Hematol 10(10):853–862. https://doi.org/10.1080/17474086.2017.1369400

    Article  CAS  PubMed  Google Scholar 

  80. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE et al (2014) Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123(21):3239–3246. https://doi.org/10.1182/blood-2013-12-540971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36(26):2684–2692. https://doi.org/10.1200/JCO.2017.77.6112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Vulaj V, Perissinotti AJ, Uebel JR, Nachar VR, Scappaticci GB, Crouch A et al (2018) The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res 70:91–96. https://doi.org/10.1016/j.leukres.2018.05.011

    Article  PubMed  Google Scholar 

  83. Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF et al (2011) Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 117(7):1463–1469. https://doi.org/10.1002/cncr.25598

    Article  PubMed  Google Scholar 

  84. Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å et al (2015) Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 90(3):208–214. https://doi.org/10.1002/ajh.23908

    Article  PubMed  Google Scholar 

  85. Vyxeos [Package insert]. Palo Alto, CA: Jazz Pharmaceuticals; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf

  86. Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J et al (2020) Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res 93:106367. https://doi.org/10.1016/j.leukres.2020.106367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V et al (2017) Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer 123(11):2025–2034. https://doi.org/10.1002/cncr.30536

    Article  CAS  PubMed  Google Scholar 

  88. Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI et al (1992) Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10(11):1723–1729. https://doi.org/10.1200/JCO.1992.10.11.1723

    Article  CAS  PubMed  Google Scholar 

  89. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF et al (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15(11):1431–1438. https://doi.org/10.1016/j.bbmt.2009.07.008

    Article  PubMed  PubMed Central  Google Scholar 

  90. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al (2005) Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108–114. https://doi.org/10.1016/j.bbmt.2004.10.008

    Article  PubMed  Google Scholar 

  91. Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE (2011) Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 39(7):741–750. https://doi.org/10.1016/j.exphem.2011.04.001

    Article  CAS  PubMed  Google Scholar 

  92. Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M et al (2021) Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma 62(9):2184–2192. https://doi.org/10.1080/10428194.2021.1907378

  93. Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M et al (2020) Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 4(13):2866–2870. https://doi.org/10.1182/bloodadvances.2020001482

    Article  PubMed  PubMed Central  Google Scholar 

  94. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S et al (2010) Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 28(5):808–814. https://doi.org/10.1200/JCO.2009.23.2652

    Article  CAS  PubMed  Google Scholar 

  95. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R et al (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16(3):872–81. https://doi.org/10.1200/JCO.1998.16.3.872

    Article  PubMed  Google Scholar 

  96. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C et al (2020) Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With. J Clin Oncol 38(26):2993–3002. https://doi.org/10.1200/JCO.19.03345

    Article  PubMed  Google Scholar 

  97. Roboz GJ, Strickland SA, Litzow MR, Dalovisio A, Perl AE, Bonifacio G et al (2020) Updated safety of midostaurin plus chemotherapy in newly diagnosed. Leuk Lymphoma 61(13):3146–3153. https://doi.org/10.1080/10428194.2020.1805109

    Article  CAS  PubMed  Google Scholar 

  98. Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ et al (2019) Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood 133(13):1457–1464. https://doi.org/10.1182/blood-2018-10-879866

    Article  CAS  PubMed  Google Scholar 

  99. Russell NH, Hills RK, Thomas A, Thomas I, Kjeldsen L, Dennis M et al (2021) Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. https://doi.org/10.3324/haematol.2021.279010

    Article  PubMed  PubMed Central  Google Scholar 

  100. Foran JM, Zhouxin S, Claxton DF, Lazarus HM, Arber DA, Rowe JM, et al (2019) Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study [abstract]. Blood. Abstract 615.

  101. Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL et al (2017) Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia 31(1):34–39. https://doi.org/10.1038/leu.2016.252

    Article  CAS  PubMed  Google Scholar 

  102. Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H et al (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med 383(26):2526–2537. https://doi.org/10.1056/NEJMoa2004444

    Article  CAS  PubMed  Google Scholar 

  103. Schlenk RF (2016) Is there justification for 4 cycles of consolidation therapy in AML? Best Pract Res Clin Haematol 29(4):341–344. https://doi.org/10.1016/j.beha.2016.10.008

    Article  PubMed  Google Scholar 

  104. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J et al (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3(12):1583–1589. https://doi.org/10.1200/JCO.1985.3.12.1583

    Article  PubMed  Google Scholar 

  105. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930

    Article  CAS  Google Scholar 

  106. Wei A, Roboz GJ, Dombret H, Döhner H, Schuh AC, Montesinos P et al (2020) CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial. Blood 136(Supplement 1):38–40

    Article  Google Scholar 

  107. Chen EY, Joshi SK, Tran A, Prasad V (2019) Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Intern Med 179(5):642–647. https://doi.org/10.1001/jamainternmed.2018.8351

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, 1540 E. Hospital Dr, Ann Arbor, MI, 48109, USA

    Madeleine A. Ochs, Bernard L. Marini, Anthony J. Perissinotti & Lydia L. Benitez

  2. University of Michigan College of Pharmacy, Ann Arbor, MI, USA

    Bernard L. Marini & Lydia L. Benitez

  3. Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine, Ann Arbor, MI, USA

    Charles E. Foucar, Kristen Pettit, Patrick Burke & Dale L. Bixby

  4. University of Michigan Medical School, Ann Arbor, MI, USA

    Charles E. Foucar, Kristen Pettit, Patrick Burke & Dale L. Bixby

Authors
  1. Madeleine A. Ochs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard L. Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony J. Perissinotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles E. Foucar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kristen Pettit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patrick Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dale L. Bixby
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lydia L. Benitez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lydia L. Benitez.

Ethics declarations

Ethics approval

This article does not contain any studies with human participants performed by any of the authors.

Conflict of interest

Kristen Pettit, MD, provides advising for the following companies: Kura Oncology, PharmaEssentia, CTI Biopharma. Anthony J. Perissinotti, PharmD, is a consultant for Servier, Amgen, and Pfizer pharmaceuticals. Bernard L. Marini, PharmD, is a consultant for Servier. None of the other authors has any conflicts of interest to disclose.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ochs, M.A., Marini, B.L., Perissinotti, A.J. et al. Oncology stewardship in acute myeloid leukemia. Ann Hematol 101, 1627–1644 (2022). https://doi.org/10.1007/s00277-022-04872-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04872-1

Keywords

Search

Navigation